The near-term progression of MED2002 into pivotal clinical trials represents a major step for Futura Medical. The enlarged trial will be powered to demonstrate the potential efficacy of MED2002 vs. placebo. Due to the planned increase in sample size, the results of the trial are now expected in H1 2016 (from Q4 2015), following which the company may seek a commercial partner. The market opportunity for MED2002 is substantial as the product could potentially be used by all men, including the esti ....
25 Jun 2015
Regulatory approval for pivotal MED2002 trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Regulatory approval for pivotal MED2002 trial
Futura Medical plc (FUM:LON) | 35.5 -0.4 (-2.7%) | Mkt Cap: 107.0m
- Published:
25 Jun 2015 -
Author:
Dr Jens Lindqvist -
Pages:
3
The near-term progression of MED2002 into pivotal clinical trials represents a major step for Futura Medical. The enlarged trial will be powered to demonstrate the potential efficacy of MED2002 vs. placebo. Due to the planned increase in sample size, the results of the trial are now expected in H1 2016 (from Q4 2015), following which the company may seek a commercial partner. The market opportunity for MED2002 is substantial as the product could potentially be used by all men, including the esti ....